Cecelia Perkins
Overview
Explore the profile of Cecelia Perkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niedoszytko M, Gorska A, Brockow K, Bonadonna P, Lange M, Kluin-Nelemans H, et al.
Allergy
. 2024 Apr;
79(9):2470-2481.
PMID: 38651829
Background: Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies...
2.
Lubke J, Schmid A, Christen D, Oude Elberink H, Span L, Niedoszytko M, et al.
Blood Adv
. 2024 Apr;
8(11):2890-2900.
PMID: 38593217
Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607...
3.
Lubke J, Schwaab J, Christen D, Elberink H, Span B, Niedoszytko M, et al.
J Allergy Clin Immunol Pract
. 2022 Nov;
11(2):581-590.e5.
PMID: 36403897
Background: Organomegaly, including splenomegaly, hepatomegaly, and/or lymphadenopathy, are important diagnostic and prognostic features in patients with cutaneous mastocytosis (CM) or systemic mastocytosis (SM). Objectives: To investigate the prevalence and prognostic...
4.
Kennedy V, Perkins C, Reiter A, Jawhar M, Lubke J, Kluin-Nelemans H, et al.
Blood Adv
. 2022 Sep;
7(9):1713-1724.
PMID: 36094848
Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the...
5.
Reiter A, Gotlib J, Alvarez-Twose I, Radia D, Lubke J, Bobbili P, et al.
Leukemia
. 2022 Jul;
36(8):2108-2120.
PMID: 35790816
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the...
6.
Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, et al.
Cell Rep Med
. 2021 Nov;
2(10):100425.
PMID: 34755136
Predicting disease progression remains a particularly challenging endeavor in chronic degenerative disorders and cancer, thus limiting early detection, risk stratification, and preventive interventions. Here, profiling the three chronic subtypes of...
7.
Zanotti R, Bonifacio M, Lucchini G, Sperr W, Scaffidi L, van Anrooij B, et al.
Leukemia
. 2021 Sep;
36(2):516-524.
PMID: 34545185
In the current classification of the World Health Organization (WHO), bone marrow mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined by bone marrow involvement and absence...
8.
Munoz-Gonzalez J, Alvarez-Twose I, Jara-Acevedo M, Zanotti R, Perkins C, Jawhar M, et al.
Lancet Haematol
. 2021 Jan;
8(3):e194-e204.
PMID: 33508247
Background: Several risk stratification models have been proposed in recent years for systemic mastocytosis but have not been directly compared. Here we designed and validated a risk stratification model for...
9.
Kluin-Nelemans H, Jawhar M, Reiter A, van Anrooij B, Gotlib J, Hartmann K, et al.
Theranostics
. 2021 Jan;
11(1):292-303.
PMID: 33391475
In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown. We examined the impact of sex on the clinical...
10.
Fuchs D, Kilbertus A, Kofler K, von Bubnoff N, Shoumariyeh K, Zanotti R, et al.
J Allergy Clin Immunol Pract
. 2020 Dec;
9(4):1705-1712.e4.
PMID: 33346151
Background: Mastocytosis in adults often presents with skin lesions. A bone marrow biopsy is necessary to confirm or exclude the presence of systemic mastocytosis (SM) in these cases. When a...